Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MASP2 | O00187 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | BCL6 | P41182 | 3/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644969 | 0.88 | ALDH1A1 (0.38) | NUDT1ALDH1A1MASP2MEN1KMT2A | |
| SCHEMBL5942175 | 0.69 | BCL6 (0.35) | ALDH1A1CDK5CDK5R1BCL6GRM4 | |
| SCHEMBL2934831 | 0.69 | ADORA2A (0.35) | ADORA2AADORA1ALDH1A1CDK5CDK5R1 | |
| SCHEMBL23963663 | 0.69 | FABP6 (0.41) | NUDT1ALDH1A1MASP2MEN1KMT2A | |
| SCHEMBL6944461 | 0.69 | CACNA1H (0.41) | ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL312294 | 0.69 | EGFR (0.38) | NUDT1ALDH1A1MASP2MEN1KMT2A | |
| SCHEMBL18042289 | 0.66 | KDM4E (0.52) | ADORA2AADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL6950878 | 0.66 | RAB9A (0.53) | ALDH1A1AOC3SMN1; SMN2 | |
| SCHEMBL25451172 | 0.66 | FABP6 (0.34) | NUDT1ALDH1A1MASP2MEN1KMT2A | |
| SCHEMBL25449335 | 0.66 | L3MBTL1 (0.42) | NUDT1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | ADORA2A 2990/4885ADORA1 2428/4885NUDT1 1855/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | ADORA2A 3126/4885ADORA1 4207/4885NUDT1 3653/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | ADORA2A 3126/4885ADORA1 4207/4885NUDT1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.